Apr 3, 2023 Press Releases
PDF Version AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrils AT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brain AT-07 (AT-04 + Brain Shuttle) demonstrated a 10-fold increase in brain penetration versus AT-04...
Apr 1, 2023 Posters & Publications
AUTHORS: S. Selvarajah1, P. Stocki2, A. Vick1, M. Klein1, N. Angell1, A. Gauhar2, S. Coker2, J. S. Foster3, S. Macy3, A. Williams3, M. Balachandran3, L.J. Rutkowski2, J. Wall3 1Attralus Inc, San Francisco, California, USA 2Ossianix Inc, Stevenage, UK 3University of...
Nov 17, 2022 Press Releases
PDF Version SAN FRANCISCO, PHILADELPHIA – Nov. 17, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with amyloidosis, and Ossianix, an antibody engineering company developing a...
Sep 7, 2022 Press Releases
PDF Version AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosis AT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer’s SAN FRANCISCO, Calif. – September 7, 2022 –...
Sep 7, 2022 Posters & Publications
AUTHORS: James S. Foster1, Spencer Guthrie2, Michael L. Klein2, Gregory Bell2, Suganya Selvarajah2, Angela D. Williams1, Manasi Balachandran1, Joseph W. Jackson1, Alan Stuckey1, Emily Martin1, Sallie Macy1, D. Craig Wooliver1, R. Eric Heidel1, Stephen J. Kennel1,...
